This announcement speaks as much to health as to the economy. The Swiss company Roche, a global giant in pharmaceuticals and diagnostics, has announced it has obtained CE marking for a test to detect Alzheimer's disease. Its name: Elecsys pTau217. Its principle: to measure the phosphorylated protein tau-217 in the blood, considered a marker linked to amyloid pathology. Beyond the technical aspects, the objective is clear: to save time in the diagnosis of a disease that, according to Roche, takes an average of three and a half years.
A sample is taken, and the diagnosis can change pace.
The CE marking is not just an administrative stamp; it's the key that unlocks commercialization within the European Economic Area, with stringent safety, performance, and quality requirements. Roche highlights a clear advantage: a blood test, less invasive than cerebrospinal fluid analysis, and easier to integrate into routine medical practice. The head of the Diagnostics division, Matt Sause, calls it a "significant step" and emphasizes the need for early intervention, at a time when research and treatments targeting early-stage disease are driving increasing pressure to identify patients faster, more effectively, and on a large scale.
The promise of more accessible screening comes with very concrete conditions: if more cases are identified, the influx will need to be managed, confirmation, support, and follow-up organized, and memory clinics prevented from becoming permanent bottlenecks. From an industrial perspective, Roche is playing a strategic card, as its diagnostics division already accounts for 22,5% of its revenue, and the group is scheduled to detail this project at an investor conference in London. In France, where approximately 1,2 million people live with a neurocognitive disorder, the arrival of standardized and widely available tools could accelerate a quiet transformation: that of diagnosis, which ceases to be a marathon and gradually becomes a more structured race.
Community
Comments
Comments are open, but protected against spam. Initial posts and comments containing links undergo manual review.
Be the first to comment on this article.